Determining the prevalence and outcomes of transthyretin amyloidosis cardiomyopathy-aortic stenosis patients undergoing valve intervention in New Brunswick

Infiltration of the heart with the protein transthyretin (TTR) commonly leads to the development of cardiomyopathy (ATTR-CM) and heart failure. Once considered rare, advancements in testing have led to the finding that ATTR-CM is much more prevalent. However, no current data exists in a Canadian population. Therefore, this project will determine the how prevalent ATTR-CM is in patients undergoing cardiac surgery at the New Brunswick Heart Center (NBHC). Furthermore, we will determine whether ATTR-CM is associated with worsened outcomes, including mortality, following an intervention. Secondary goals of this proposal include identifying TTR gene variants in our patient population that may promote/accelerate the development of ATTR-CM and identifying new markers in blood and tissue samples that can more easily identify ATTR-CM in patients. This proposal will serve to address a critical knowledge gap for the NBHC and will help develop an appropriate understanding and care of ATTR-CM. Our project will also position the NBHC as an amyloid center of excellence in Canada.

Kenneth D'Souza
Faculty Supervisor: 
Keith Brunt
New Brunswick
Partner University: